{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:48:08Z","timestamp":1790851688852,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017650","name":"Three Lakes Foundation","doi-asserted-by":"crossref","award":["TLF-1"],"award-info":[{"award-number":["TLF-1"]}],"id":[{"id":"10.13039\/100017650","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Create a timeline of diagnosis and treatment for IPF in the US.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Design, setting, and participants<\/jats:title>\n                <jats:p>A retrospective analysis was performed in collaboration with the OptumLabs Data Warehouse using an administrative claims database of Medicare Fee for Service beneficiaries. Adults 50 and over with IPF were included (2014 to 2019).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Exposure<\/jats:title>\n                <jats:p>To focus on IPF, the following diagnoses were excluded: post-inflammatory fibrosis, hypersensitivity pneumonitis, rheumatoid arthritis, sarcoidosis, scleroderma, and connective tissue disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main outcomes and measures<\/jats:title>\n                <jats:p>Data were collected from periods prior, during, and following initial clinical diagnosis of IPF. This included prior respiratory diagnoses, number of respiratory-related hospitalizations, anti-fibrotic and oxygen use, and survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 44,891 with IPF were identified. The most common diagnoses prior to diagnosis of IPF were upper respiratory infections (47%), acute bronchitis (13%), other respiratory disease (10%), chronic obstructive pulmonary disease and bronchiectasis (7%), and pneumonia (6%). The average time to a diagnosis of IPF was 2.7 years after initial respiratory diagnosis. Half of patients had two or more respiratory-related hospitalizations prior to IPF diagnosis. Also, 37% of patients were prescribed oxygen prior to diagnosis of IPF. These observations suggest delayed diagnosis. We also observed only 10.4% were treated with anti-fibrotics. Overall survival declined each year after diagnosis with median survival of 2.80 years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions and relevance<\/jats:title>\n                <jats:p>Our retrospective cohort demonstrates that IPF is often diagnosed late, usually preceded by other respiratory diagnoses and hospitalizations. Use of available therapies is low and outcomes remain poor.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-023-02565-7","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T14:02:58Z","timestamp":1690984978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Idiopathic pulmonary fibrosis in the United States: time to diagnosis and treatment"],"prefix":"10.1186","volume":"23","author":[{"given":"Michelle B.","family":"Herberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor T.","family":"Teague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viengneesee","family":"Thao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R.","family":"Sangaralingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry J.","family":"Henk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin T.","family":"Hovde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Dempsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Limper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,2]]},"reference":[{"key":"2565_CR1","doi-asserted-by":"crossref","unstructured":"Barratt SL, Creamer A, Hayton C, Chaudhuri N. Idiopathic pulmonary fibrosis (IPF): an overview. J Clin Med 2018, 7.","DOI":"10.3390\/jcm7080201"},{"key":"2565_CR2","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.mayocp.2014.03.016","volume":"89","author":"JH Ryu","year":"2014","unstructured":"Ryu JH, Moua T, Daniels CE, Hartman TE, Yi ES, Utz JP, Limper AH. Idiopathic pulmonary fibrosis: evolving concepts. Mayo Clin Proc. 2014;89:1130\u201342.","journal-title":"Mayo Clin Proc"},{"key":"2565_CR3","doi-asserted-by":"crossref","unstructured":"Moor CC, Wijsenbeek MS, Balestro E, Biondini D, Bondue B, Cottin V, Flewett R, Galvin L, Jones S, Molina-Molina M et al. Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey. ERJ Open Res 2019, 5.","DOI":"10.1183\/23120541.00124-2019"},{"key":"2565_CR4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1164\/rccm.201902-0456OC","volume":"200","author":"TM Dempsey","year":"2019","unstructured":"Dempsey TM, Sangaralingham LR, Yao X, Sanghavi D, Shah ND, Limper AH. Clinical effectiveness of antifibrotic medications for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2019;200:168\u201374.","journal-title":"Am J Respir Crit Care Med"},{"key":"2565_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12890-021-01607-2","volume":"21","author":"BT Kelly","year":"2021","unstructured":"Kelly BT, Thao V, Dempsey TM, Sangaralingham LR, Payne SR, Teague TT, Moua T, Shah ND, Limper AH. Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications. BMC Pulm Med. 2021;21:239.","journal-title":"BMC Pulm Med"},{"key":"2565_CR6","doi-asserted-by":"crossref","unstructured":"Behr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M, Klotsche J, Andreas S, Claussen M, Grohe C et al. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. Eur Respir J 2020, 56.","DOI":"10.1183\/13993003.02279-2019"},{"key":"2565_CR7","first-page":"204","volume":"25","author":"T Morrow","year":"2019","unstructured":"Morrow T. Improving outcomes and managing costs in idiopathic pulmonary fibrosis. Am J Manag Care. 2019;25:204\u2013S209.","journal-title":"Am J Manag Care"},{"key":"2565_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12931-019-1043-9","volume":"20","author":"L Snyder","year":"2019","unstructured":"Snyder L, Neely ML, Hellkamp AS, O\u2019Brien E, de Andrade J, Conoscenti CS, Leonard T, Bender S, Gulati M, Culver DA, et al. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respir Res. 2019;20:105.","journal-title":"Respir Res"},{"key":"2565_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12931-020-1296-3","volume":"21","author":"AW Wong","year":"2020","unstructured":"Wong AW, Ryerson CJ, Guler SA. Progression of fibrosing interstitial lung disease. Respir Res. 2020;21:32.","journal-title":"Respir Res"},{"key":"2565_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2147\/PROM.S144425","volume":"9","author":"BA Graney","year":"2018","unstructured":"Graney BA, Lee JS. Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives. Patient Relat Outcome Meas. 2018;9:321\u20138.","journal-title":"Patient Relat Outcome Meas"},{"key":"2565_CR11","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1377\/hlthaff.2014.0038","volume":"33","author":"PJ Wallace","year":"2014","unstructured":"Wallace PJ, Shah ND, Dennen T, Bleicher PA, Crown WH. Optum Labs: building a novel node in the learning health care system. Health Aff (Millwood). 2014;33:1187\u201394.","journal-title":"Health Aff (Millwood)"},{"key":"2565_CR12","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1513\/AnnalsATS.202007-901OC","volume":"18","author":"TM Dempsey","year":"2021","unstructured":"Dempsey TM, Payne S, Sangaralingham L, Yao X, Shah ND, Limper AH. Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for patients with idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2021;18:1121\u20138.","journal-title":"Ann Am Thorac Soc"},{"key":"2565_CR13","unstructured":"AHRQ: HCUP Clinical Classifications Software for ICD-9-CM. Healthcare Cost and Utilization Project (HCUP). 2006\u20132011. AHRQ published online Accessed 2021."},{"key":"2565_CR14","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1001\/jama.2018.6024","volume":"319","author":"X Yao","year":"2018","unstructured":"Yao X, Gersh BJ, Holmes DR Jr, Melduni RM, Johnsrud DO, Sangaralingham LR, Shah ND, Noseworthy PA. Association of Surgical Left Atrial appendage occlusion with subsequent stroke and mortality among patients undergoing cardiac surgery. JAMA. 2018;319:2116\u201326.","journal-title":"JAMA"},{"key":"2565_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2307\/2340521","volume":"85","author":"RA Fisher","year":"1922","unstructured":"Fisher RA. On the interpretation of \u03c7 2 from contingency tables, and the calculation of P. J Roy Stat Soc. 1922;85:87\u201394.","journal-title":"J Roy Stat Soc"},{"key":"2565_CR16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1183\/09059180.00002512","volume":"21","author":"L Nalysnyk","year":"2012","unstructured":"Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev. 2012;21:355\u201361.","journal-title":"Eur Respir Rev"},{"key":"2565_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","volume":"183","author":"B Ley","year":"2011","unstructured":"Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431\u201340.","journal-title":"Am J Respir Crit Care Med"},{"key":"2565_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12931-019-1161-4","volume":"20","author":"TM Maher","year":"2019","unstructured":"Maher TM, Strek ME. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respir Res. 2019;20:205.","journal-title":"Respir Res"},{"key":"2565_CR19","doi-asserted-by":"publisher","first-page":"e232427","DOI":"10.1001\/jamanetworkopen.2023.2427","volume":"6","author":"A Adegunsoye","year":"2023","unstructured":"Adegunsoye A, Freiheit E, White EN, Kaul B, Newton CA, Oldham JM, Lee CT, Chung J, Garcia N, Ghodrati S, et al. Evaluation of pulmonary fibrosis outcomes by race and ethnicity in US adults. JAMA Netw Open. 2023;6:e232427.","journal-title":"JAMA Netw Open"},{"key":"2565_CR20","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s12020-021-02710-4","volume":"73","author":"RG McCoy","year":"2021","unstructured":"McCoy RG, Van Houten HK, Dunlay SM, Yao X, Dempsey T, Noseworthy PA, Sangaralingham LR, Limper AH, Shah ND. Race and sex differences in the initiation of diabetes drugs by privately insured US adults. Endocrine. 2021;73:480\u20134.","journal-title":"Endocrine"},{"key":"2565_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","volume":"8","author":"AU Wells","year":"2020","unstructured":"Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8:453\u201360.","journal-title":"Lancet Respir Med"},{"key":"2565_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12890-017-0560-x","volume":"18","author":"GP Cosgrove","year":"2018","unstructured":"Cosgrove GP, Bianchi P, Danese S, Lederer DJ. Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey. BMC Pulm Med. 2018;18:9.","journal-title":"BMC Pulm Med"},{"key":"2565_CR23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/resp.14154","volume":"27","author":"L Lancaster","year":"2022","unstructured":"Lancaster L, Bonella F, Inoue Y, Cottin V, Siddall J, Small M, Langley J. Idiopathic pulmonary fibrosis: physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden. Respirology. 2022;27:66\u201375.","journal-title":"Respirology"},{"key":"2565_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12931-019-1076-0","volume":"20","author":"N Hoyer","year":"2019","unstructured":"Hoyer N, Prior TS, Bendstrup E, Wilcke T, Shaker SB. Risk factors for diagnostic delay in idiopathic pulmonary fibrosis. Respir Res. 2019;20:103.","journal-title":"Respir Res"},{"key":"2565_CR25","doi-asserted-by":"crossref","unstructured":"Hoyer N, Prior TS, Bendstrup E, Shaker SB. Diagnostic delay in IPF impacts progression-free survival, quality of life and hospitalisation rates. BMJ Open Respir Res 2022, 9.","DOI":"10.1136\/bmjresp-2022-001276"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02565-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-023-02565-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02565-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T14:03:21Z","timestamp":1690985001000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-023-02565-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2565"],"URL":"https:\/\/doi.org\/10.1186\/s12890-023-02565-7","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,2]]},"assertion":[{"value":"12 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data was acquired in accordance with relevant guidelines and regulations of the National Institutes of Health and the Mayo Clinic Institutional Review Boards consistent with the Declaration of Helsinki. Ethics approval and informed consent was waived by the Mayo Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"281"}}